NVCR - NovoCure Making Remarkable Progress; Buy
NovoCure Limited (NVCR) is a ~$7.9 billion market capitalization oncology device company that provides patients with a new cancer treatment based on alternating electric field technology. The company's lead product is based on the research work of founder Yoram Palti that such electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This use of such Tumor Treating Fields (TTFields) represents a completely innovative approach to cancer therapy and is no longer confined to the laboratory or experimental setting, as the company's revenue topline continues to grow significantly.